LME 636

Drug Profile

LME 636

Alternative Names: ESBA 1622; LME636

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ESBATech
  • Developer Alcon
  • Class Anti-inflammatories; Antibodies; Eye disorder therapies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry eyes; Uveitis

Most Recent Events

  • 11 Sep 2017 Phase-II development is ongoing in USA (Apexigen pipeline, September 2017)
  • 01 Mar 2016 Alcon Research completes a phase II trial in Uveitis in USA (Ophthalmic) (NCT02482129)
  • 01 Oct 2015 Alcon Research completes a phase II trial in Dry eyes in USA (NCT02365519)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top